Clinical Trial Update: EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Cyclo 3 Fort (ruscus extract, hesperidin methyl chalcone, ascorbic acid) or micronised purified flavonoid fraction on vascular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Disease
• Venous Insufficiency

Drugs mentioned

• Cyclo 3 Fort (Ruscus extract; hesperidin methyl chalcone; ascorbic acid)
• Micronised purified flavonoid fraction (Diosmin and hesperidin (micronised purified flavonoid fraction))

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Venous Disease Classification (CEAP): C2 or C3 | Phase 2 | Status: WITHDRAWN